<DOC>
	<DOCNO>NCT01768507</DOCNO>
	<brief_summary>Heme oxygenase 1 ( HO-1 ) serve protective gene . The aim clinical trial evaluate HO-1 stimulation resveratrol healthy human .</brief_summary>
	<brief_title>Reresveratrol Administered Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure . Male patient age 18 45 year ( inclusive ) screening . No clinically significant finding physical examination screening . Body mass index ( BMI ) 18 28 kg/m2 ( inclusive ) screening . Nonsmoker ( least 1 month ) Hematology , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent screening . Negative result urine drug screen screen . Ability communicate well investigator , local language , understand comply requirement study . Known hypersensitivity resveratrol excipients resveratrol formulation . Treatment investigational drug within 3 week prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion resveratrol . Smoker Previous treatment prescribe OTC medication ( include herbal medicine St John 's Wort ) within 2 week prior screen . Regularly intake resveratrol rich food Positive result hepatitis serology screening . Positive result HIV serology screen . Presumed noncompliance . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>